AffiliationUniversity of Leeds, St James' University Hospital, Leeds, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractPURPOSE OF REVIEW: Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. Methods of early detection, as well as improved therapeutic options, are urgently needed. RECENT FINDINGS: Currently, a number of targeted therapies, including vascular endothelial growth factor inhibitors, poly-ADP-ribose polymerase inhibitors and folate receptor inhibitors look promising in this arena and this article will review a number of these drugs and the evidence pertaining to their use. SUMMARY: Much further research is required to define if, when and how best to integrate these novel therapies, and also to define associated biomarkers that predict toxicity and select patients most likely to derive benefit. Individualized therapy is not an impossible dream, but there is still a long way to go.
CitationNew therapeutic agents in ovarian cancer. 2009, 21 (1):44-53 Curr. Opin. Obstet. Gynecol.
JournalCurrent Opinion in Obstetrics & Gynecology
- Targeted agents in ovarian cancer.
- Authors: Kristedja TS, Morgan RJ, Cristea M
- Issue date: 2010 Sep
- New drugs for ovarian cancer.
- Authors: Kaye SB
- Issue date: 2008 Feb
- Angiogenesis as a target for the treatment of ovarian cancer.
- Authors: Shaw D, Clamp A, Jayson GC
- Issue date: 2013 Sep
- Bevacizumab in the treatment of ovarian cancer.
- Authors: Han ES, Monk BJ
- Issue date: 2007 Oct
- Angiogenesis as a strategic target for ovarian cancer therapy.
- Authors: Spannuth WA, Sood AK, Coleman RL
- Issue date: 2008 Apr